Q32 Bio Inc (QTTB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$8.85-1.34%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · QTTB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -85.5% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 116 industry peers
QTTB — litigation filed
Dated 2026-09-30
Other Events. On September 30, 2026, the Company announced additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe alopecia areata (“AA”). These results were presented across a late-breaking oral and poster presentation at the European Academy of Dermatology and Venereology (“EADV”) Congress 2026. The Company previously announced topline results from this…
Why it matters: A trial start would move bempikibart beyond its small, open-label Phase 2 study. A delay would push back the next major test.
Supportive ifBy June 30, 2027, Q32 says the registration-directed trial is open and the first patient has received a dose.
Worry ifQ32 has not started the trial by June 30, 2027, or announces a later start date.
Why it matters: Q32 plans to start a registration-directed trial in early 2027, after talks with regulators. Clear FDA alignment would support that timing.
Supportive ifQ32 reports FDA agreement on the trial design and keeps a first-half 2027 start date.
Worry ifQ32 reports that FDA feedback requires major trial changes or delays the planned start beyond the first half of 2027.
Why it matters: The drug aims to use the same target as bempikibart with less frequent dosing. A move beyond preclinical work would show progress on that plan.
Supportive ifQ32 says ADX-914-XL has entered human testing or gives a date for the first human trial to start.
Worry ifQ32 pauses or ends ADX-914-XL development, or reports no move beyond preclinical work by its next update.
Why it matters: These results can test whether hair growth lasts with ongoing treatment and help set a maintenance dose. Weak results could challenge the durability case.
Watch forQ32 reports extension data from the second half of 2027. The data show lasting hair growth and support maintenance every month, every other month, or every quarter.
Also watch forQ32 reports that hair growth fades during extension treatment, or delays the data beyond the second half of 2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$243 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $1,024 loss on $10,000 · 10.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,483 loss on $10,000 · 64.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Q32 says cash from its offering should fund work through Phase 3 results. A shorter runway could force new funding before that test.
Worry ifQ32 reports that its cash still covers planned work through Phase 3 topline results, with no added financing needed for that plan.
Less concerning ifQ32 says cash no longer covers the plan through Phase 3 results or announces new financing to fund it.
Why it matters: Part B reported no treatment-related serious or severe events. A new safety problem could weaken the case for a longer trial.
Worry ifA future trial report lists a serious event linked to treatment or a new severe safety signal.
Less concerning ifIn its next trial update, Q32 reports no new safety signals and no serious or severe events linked to treatment.